封面
市場調查報告書
商品編碼
1423331

2024-2032 年按測試類型(血液檢查、影像學測試、肝臟活體組織切片)和地區分類的肝炎診斷測試市場報告

Hepatitis Diagnostic Tests Market Report by Test Type (Blood Tests, Imaging Test, Liver Biopsy), and Region 2024-2032

出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

2023年,全球肝炎診斷檢測市場規模達到58億美元。展望未來, IMARC Group預計到2032年市場規模將達到88億美元,2024-2032年複合年成長率(CAGR)為4.5%。由於全球肝炎盛行率不斷上升、診斷技術的快速進步、公眾意識和篩檢措施的提高、政府支持性政策和資金的實施以及健康保險覆蓋範圍和報銷政策的擴大,該市場正在經歷強勁成長。

肝炎診斷測試市場分析:

市場成長與規模:在全球肝炎盛行率上升、診斷技術快速進步以及健康保險覆蓋範圍和報銷政策擴大的推動下,市場正在穩定成長。

主要市場促進因素:影響市場成長的主要促進因素包括肝炎發病率的上升、檢測方法的快速進步、全球範圍內對肝炎預防和治療的認知不斷提高以及政府舉措和資金的實施。

主要市場趨勢:主要市場趨勢涉及在技術創新的推動下向非侵入性和快速檢測方法的持續轉變。此外,人們越來越關注床邊檢測(POC​​T)和個人化醫療,以加強肝炎的早期檢測和管理,這也促進了市場的成長。

地理趨勢:北美因其先進的醫療保健系統和高認知水平而引領市場。在醫療基礎設施不斷完善和政府支持性措施實施的推動下,其他地區也出現了顯著成長。

競爭格局:市場的特點是主要參與者積極參與,他們專注於研發(R&D)以引入先進的診斷技術。此外,公司正在進行策略合作、合併和收購,以擴大市場佔有率並增強產品組合。

挑戰與機會:市場面臨各種挑戰,例如醫療保健取得的差異,特別是在低度開發地區,以及對具有成本效益的檢測解決方案的需求。然而,不斷湧現的創新以及醫療保健服務向新興市場的擴張正在為市場成長創造新的機會。

肝炎診斷測試市場趨勢:

全球肝炎盛行率不斷上升

乙型肝炎和丙型肝炎等肝炎盛行率的增加是推動市場成長的主要因素之一。此外,人們對早期肝炎無症狀性質的認知不斷增強,增加了對診斷測試的需求,從而促進了市場的成長。除此之外,透過輸血傳播、不安全注射操作以及出生期間母嬰傳播的病例不斷增加,正在推動市場成長。同時,對肝炎患者的早期診斷和定期監測的需求不斷增加,以控制疾病並防止其進展到肝硬化和肝細胞癌等嚴重階段,這正在促進市場的成長。與此一致的是,由於檢測病毒是否存在、評估肝功能和監測治療效果的必要性,對診斷測試的需求不斷增加,正在促進市場成長。

診斷技術的快速進步

測試方法的快速技術進步和創新,導致更準確、更有效率、侵入性更小的測試的發展,正在促進市場成長。此外,現代診斷工具的發展,如新一代定序(NGS)、即時聚合酶鍊式反應(PCR)和快速診斷測試(RDT),可提供更快的結果、更高的靈敏度和特異性,正在發揮作用。生長誘導因子。它們提高了肝炎診斷的準確性並減少了獲得結果所需的時間。除此之外,即時檢測(POC​​T)的快速進步使得在傳統實驗室環境之外進行肝炎檢測成為可能,正在推動市場成長。除此之外,在公共和私營部門大量投資的支持下,為滿足醫療保健提供者和患者不斷變化的需求而進行的診斷技術研發(R&D)正在推動市場成長。

提高疾病意識和教育活動

人們對肝炎及其影響的認知不斷提高,導致廣泛的篩檢和檢測,是推動市場成長的主要因素之一。與此一致,各政府衛生機構、非營利組織 (NGO) 和醫療保健提供者越來越關注教育大眾與肝炎相關的風險以及早期診斷和治療的重要性,這正在促進市場成長。同時,多項宣傳活動的推出,促進個人接受自願檢測,也刺激了市場的成長。此外,人們不斷努力提高對該疾病的普遍了解,例如不安全的注射做法、未經篩檢的輸血和無保護的性接觸,也促進了市場的成長。

落實政府各項舉措

政府採取各種措施來提高肝炎診斷服務的覆蓋範圍和效率是加強市場成長的主要因素。此外,對研究、診斷設施開發以及對國家肝炎控制計劃的支持不斷增加的投資正在推動市場的成長。除此之外,與國際組織不斷加強合作,制定和實施肝炎預防、診斷和治療策略,確保在各種醫療保健環境中進行高品質檢測,這為市場成長提供了相當大的推動力。此外,政府資助有助於補貼診斷測試的費用,使更廣泛的人群更容易獲得這些測試。

擴大醫療保險覆蓋範圍和報銷政策

醫療保險覆蓋率的擴大和優惠報銷政策的製定是有利於市場成長的關鍵驅動力。此外,人們越來越認知到肝炎是一個公共衛生問題,促使健康保險提供者將肝炎診斷測試涵蓋其承保服務的一部分,從而擴大了市場的成長。除此之外,政府資助的保險計劃的推出,涵蓋肝炎檢測,同時鼓勵個人尋求早期診斷,正在促進市場成長。此外,人們對報銷政策的日益關注,有助於醫療保健提供者向患者推薦測試,預計將推動市場成長。報銷可以激勵實驗室和診斷中心提供更廣泛的肝炎檢測,從而提高先進檢測選項的可用性。

目錄

第1章:前言

第 2 章:範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章:執行摘要

第 4 章:簡介

  • 概述
  • 主要行業趨勢

第 5 章:全球肝炎診斷測試市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場區隔:按測試類型
  • 市場區隔:按地區
  • 市場預測
  • SWOT分析
    • 概述
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • 價值鏈分析
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅
  • 價格分析

第 6 章:市場區隔:按測試類型

  • 血液檢查
    • 市場走向
    • 市場預測
  • 影像學檢查
    • 市場走向
    • 市場預測
  • 肝臟活體組織切片
    • 市場走向
    • 市場預測

第 7 章:市場區隔:按地區

  • 北美洲
    • 市場走向
    • 市場預測
  • 亞太地區
    • 市場走向
    • 市場預測
  • 歐洲
    • 市場走向
    • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場預測
  • 拉丁美洲
    • 市場走向
    • 市場預測

第 8 章:競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Siemens AG
    • Abbott Laboratories
    • MedMira Inc
    • Qiagen GmbH
    • Beckman Coulter Inc (Danaher Corporation)
    • F. Hoffmann- La Roche AG
    • Diasorin SpA
    • bioMeriuex SA
    • Hologic Inc
    • Bio-Rad Laboratories Inc
Product Code: SR112024A1132

Abstract

The global hepatitis diagnostic tests market size reached US$ 5.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.8 Billion by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032. The market is experiencing robust growth, driven by the rising prevalence of hepatitis across the globe, rapid technological advancements in diagnostics, increasing public awareness and screening initiatives, implementation of supportive government policies and funding, and the expansion of health insurance coverage and reimbursement policies.

Hepatitis Diagnostic Tests Market Analysis:

Market Growth and Size: The market is witnessing stable growth, driven by the rising prevalence of hepatitis across the globe, rapid advancements in diagnostic technologies, and the expansion of health insurance coverage and reimbursement policies.

Major Market Drivers: Key drivers influencing the market growth include the growing incidence of hepatitis, rapid advancements in testing methods, rising awareness about hepatitis prevention and treatment across the globe, and the imposition of government initiatives and funding.

Key Market Trends: The key market trends involve the ongoing shift towards non-invasive and rapid testing methods, driven by technological innovation. Additionally, the increasing focus on point-of-care testing (POCT) and personalized medicine to enhance early detection and management of hepatitis, is bolstering the market growth.

Geographical Trends: North America leads the market due to its advanced healthcare system and high awareness levels. Other regions are also showing significant growth, fueled by rising healthcare infrastructure and implementation of supportive government initiatives.

Competitive Landscape: The market is characterized by the active involvement of key players who are focusing on research and development (R&D) to introduce advanced diagnostics. Furthermore, companies are engaging in strategic partnerships, mergers, and acquisitions to expand their market presence and enhance product portfolios.

Challenges and Opportunities: The market faces various challenges, such as disparities in healthcare access, particularly in underdeveloped regions, and the need for cost-effective testing solutions. However, the rising innovation, and expansion of healthcare services into emerging markets are creating new opportunities for the market growth.

Hepatitis Diagnostic Tests Market Trends:

Increasing prevalence of hepatitis across the globe

The increasing prevalence of hepatitis, such as hepatitis B and C, is one of the major factors propelling the market growth. Moreover, the growing awareness about the asymptomatic nature of early-stage hepatitis, boosting the need for diagnostic tests, is catalyzing the market growth. Besides this, the burgeoning cases of transmission through blood transfusion, unsafe injection practices, and mother-to-child transmission during birth, are fueling the market growth. Along with this, the rising need for early diagnosis and regular monitoring of patients with hepatitis for managing the disease and preventing its progression to severe stages, such as liver cirrhosis and hepatocellular carcinoma, is catalyzing the market growth. In line with this, the increasing demand for diagnostic tests, driven by the necessity to detect the presence of the virus, assess liver function, and monitor the effectiveness of treatment, is enhancing the market growth.

Rapid advancements in diagnostic technologies

The rapid technological advancements and innovations in testing methodologies, leading to the development of more accurate, efficient, and less invasive tests, are fostering the market growth. Moreover, the development of modern diagnostic tools, such as next-generation sequencing (NGS), real-time polymerase chain reaction (PCR), and rapid diagnostic tests (RDTs) that offer faster results with higher sensitivity and specificity, are acting as a growth-inducing factor. They enhance the accuracy of hepatitis diagnosis and reduce the time required to obtain results. In addition to this, rapid advancements in point-of-care testing (POCT), making it possible to conduct hepatitis tests outside traditional laboratory settings, are fueling the market growth. Besides this, the ongoing research and development (R&D) in diagnostic technologies, supported by substantial investments from public and private sectors, to meet the evolving needs of healthcare providers and patients is driving the market growth.

Rising disease awareness and educational campaigns

The increasing awareness about hepatitis and its implications, leading to widespread screening and testing, is one of the major factors propelling the market growth. In line with this, the growing focus of various governmental health bodies, non-profit organizations (NGOs), and healthcare providers to educate the public about the risks associated with hepatitis and the importance of early diagnosis and treatment is bolstering the market growth. Along with this, the introduction of several awareness campaigns promoting individuals to undergo voluntary testing is stimulating the market growth. Furthermore, the rising efforts to increase the general understanding of the disease, such as unsafe injection practices, unscreened blood transfusions, and unprotected sexual contact, are contributing to the market growth.

Implementation of various government initiatives

The imposition of various government initiatives to enhance the reach and efficiency of hepatitis diagnostic services is a major factor strengthening the market growth. Moreover, the increasing investment in research, development of diagnostic facilities, and support for national hepatitis control programs, is fueling the market growth. In addition to this, the growing collaborations with international organizations to develop and implement strategies for hepatitis prevention, diagnosis, and treatment that ensure high-quality testing across various healthcare settings are providing a considerable boost to the market growth. Additionally, government funding aids in subsidizing the cost of diagnostic tests, making them more accessible to a broader section of the population.

Expansion of health insurance coverage and reimbursement policies

The expansion of health insurance coverage and the development of favorable reimbursement policies are key drivers favoring the market growth. Moreover, the increasing recognition of hepatitis as a public health issue, prompting health insurance providers to include hepatitis diagnostic tests as part of their covered services, is amplifying the market growth. Besides this, the introduction of government-funded insurance schemes that cover hepatitis testing while encouraging individuals to seek early diagnosis is catalyzing the market growth. Furthermore, the growing focus on your reimbursement policies, facilitating healthcare providers to recommend the tests to their patients, is anticipated to drive the market growth. Reimbursement incentivizes laboratories and diagnostic centers to offer a wider range of hepatitis tests, enhancing the availability of advanced testing options.

Hepatitis Diagnostic Tests Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on test type.

Breakup by Test Type:

Blood Tests

Imaging Test

Liver Biopsy

Blood tests accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the test type. This includes blood tests, imaging test, and liver biopsy. According to the report, blood tests represented the largest segment.

Blood tests hold the largest market share due to their widespread availability, ease of use, and cost-effectiveness. They include enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and liver function tests to detect the presence of hepatitis viruses and assess liver damage. Moreover, the high sensitivity and specificity of the tests, making them the first line of diagnosis in most healthcare settings, is boosting the market growth. Additionally, rapid advancements in blood testing technologies, such as rapid diagnostic tests and point-of-care testing (POCT) devices, are anticipated to drive the market growth. Besides this, the increasing utilization of blood tests for large-scale screening programs, especially in areas with high prevalence rates, is bolstering the market growth.

Imaging tests include methods such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI). They are utilized to assess the extent of liver damage in chronic hepatitis cases and to detect conditions like liver cirrhosis or liver cancer. Moreover, the growing importance of imaging tests in the staging of liver disease and guiding decisions regarding the need for more invasive procedures is favoring the market growth.

Liver biopsy involves the extraction of a small liver tissue sample for microscopic examination, providing detailed information about the extent of liver inflammation and fibrosis. They are employed in cases where blood and imaging tests are inconclusive or to assess the severity of liver damage more accurately. Moreover, liver biopsies offer critical insights in complex cases, influencing treatment decisions and management of chronic hepatitis patients.

Breakup by Region:

North America

Asia Pacific

Europe

Middle East and Africa

Latin America

North America leads the market, accounting for the largest hepatitis diagnostic tests market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Asia Pacific, Europe, the Middle East and Africa and Latin America. According to the report, North America accounted for the largest market share.

North America dominates the market due to its advanced healthcare infrastructure, high awareness levels about hepatitis, and substantial investment in healthcare. Moreover, the widespread adoption of cutting-edge diagnostic technologies, comprehensive screening programs, and robust government policies supporting hepatitis research and public health initiatives in the region are favoring the market growth. Along with this, the growing focus on early detection and prevention, driven by collaborations between healthcare providers, government agencies, and private organizations, is creating a positive outlook for the market growth. Besides this, the heightened research and development (R&D) activities, contributing to the introduction of innovative diagnostic solutions, are fueling the market growth.

The Asia Pacific region market is rapidly growing due to the high prevalence of hepatitis in the region, coupled with improving healthcare infrastructure, increasing public and private healthcare expenditure, and rising awareness about hepatitis and its implications. Moreover, the implementation of several government-funded large-scale screening and vaccination programs is bolstering the market growth.

Europe's hepatitis diagnostic tests market is growing, attributed to its well-established healthcare systems, high awareness of hepatitis, and strong government support for healthcare initiatives. Moreover, the widespread implementation of hepatitis screening and vaccination programs, is fueling the market growth. Besides this, the presence of leading healthcare companies and advanced research facilities in the region, contributing to the development and adoption of innovative diagnostic technologies, is fostering the market growth.

In Latin America, the hepatitis diagnostic tests market is growing, driven by the increasing prevalence of hepatitis. Moreover, the rising efforts to improve healthcare infrastructure and access to medical services are contributing to the market growth. Along with this, the growing focus by the governments and healthcare organizations in the region on awareness campaigns and improving diagnostic and treatment services for hepatitis is enhancing the market growth.

The market in the Middle East and Africa is evolving, with an increasing focus on addressing hepatitis. Moreover, the rising focus on enhancing healthcare services, with an emphasis on infectious disease control and prevention, is creating a positive outlook for the market. Additionally, the growing investment in healthcare and the adoption of modern diagnostic technologies are contributing to the market growth.

Leading Key Players in the Hepatitis Diagnostic Tests Industry:

The major players are engaged in a range of strategic activities to strengthen their market positions. They are investing in research and development (R&D) to introduce more advanced, accurate, and user-friendly diagnostic tests. Moreover, some companies are focusing on developing rapid and non-invasive testing methods that can provide quicker results with high accuracy. Besides this, they are involved in collaborations and partnerships with healthcare organizations, government bodies, and research institutions to enhance their product offerings and expand their geographical reach. Additionally, the leading firms are participating in awareness campaigns and educational programs to increase public knowledge about hepatitis and the importance of early diagnosis.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Siemens AG

Abbott Laboratories

MedMira Inc

Qiagen GmbH

Beckman Coulter Inc (Danaher Corporation)

F. Hoffmann- La Roche AG

Diasorin S.p.A

bioMeriuex SA

Hologic Inc.

Bio-Rad Laboratories Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

In May 2023, Beckman Coulter Inc (Danaher Corporation) unveiled its next-generation immunoassay analyzer and the DxI 9000 Immunoassay Analyzer with increased assay development sensitivity.

In November 2023, Diasorin announced the development of the first fully automated diagnostic test for hepatitis delta virus (HDV) on the Diasorin LIAISON XL immunoassay system in the United States.

In May 2022, Abbott launched the HBsAg next qualitative solution in India that improved and enhanced the identification of the Hepatitis B virus (HBV).

Key Questions Answered in This Report

  • 1. What was the size of the global hepatitis diagnostic tests market in 2023?
  • 2. What is the expected growth rate of the global hepatitis diagnostic tests market during 2024-2032?
  • 3. What are the key factors driving the global hepatitis diagnostic tests market?
  • 4. What has been the impact of COVID-19 on the global hepatitis diagnostic tests market?
  • 5. What is the breakup of the global hepatitis diagnostic tests market based on the test type?
  • 6. What are the key regions in the global hepatitis diagnostic tests market?
  • 7. Who are the key players/companies in the global hepatitis diagnostic tests market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hepatitis Diagnostic Tests Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Test Type
  • 5.5 Market Breakup by Region
  • 5.6 Market Forecast
  • 5.7 SWOT Analysis
    • 5.7.1 Overview
    • 5.7.2 Strengths
    • 5.7.3 Weaknesses
    • 5.7.4 Opportunities
    • 5.7.5 Threats
  • 5.8 Value Chain Analysis
  • 5.9 Porters Five Forces Analysis
    • 5.9.1 Overview
    • 5.9.2 Bargaining Power of Buyers
    • 5.9.3 Bargaining Power of Suppliers
    • 5.9.4 Degree of Competition
    • 5.9.5 Threat of New Entrants
    • 5.9.6 Threat of Substitutes
  • 5.10 Price Analysis

6 Market Breakup by Test Type

  • 6.1 Blood Tests
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Imaging Test
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Liver Biopsy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Asia Pacific
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Europe
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Middle East and Africa
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Latin America
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Key Players
  • 8.3 Profiles of Key Players
    • 8.3.1 Siemens AG
    • 8.3.2 Abbott Laboratories
    • 8.3.3 MedMira Inc
    • 8.3.4 Qiagen GmbH
    • 8.3.5 Beckman Coulter Inc (Danaher Corporation)
    • 8.3.6 F. Hoffmann- La Roche AG
    • 8.3.7 Diasorin S.p.A
    • 8.3.8 bioMeriuex SA
    • 8.3.9 Hologic Inc
    • 8.3.10 Bio-Rad Laboratories Inc

List of Figures

  • Figure 1: Global: Hepatitis Diagnostic Tests Market: Major Drivers and Challenges
  • Figure 2: Global: Hepatitis Diagnostic Tests Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hepatitis Diagnostic Tests Market: Breakup by Test Type (in %), 2023
  • Figure 4: Global: Hepatitis Diagnostic Tests Market: Breakup by Region (in %), 2023
  • Figure 5: Global: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 6: Global: Hepatitis Diagnostic Tests Industry: SWOT Analysis
  • Figure 7: Global: Hepatitis Diagnostic Tests Industry: Value Chain Analysis
  • Figure 8: Global: Hepatitis Diagnostic Tests Industry: Porter's Five Forces Analysis
  • Figure 9: Global: Hepatitis Diagnostic Tests (Blood Test) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hepatitis Diagnostic Tests (Blood Tests) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hepatitis Diagnostic Tests (Imaging Test) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hepatitis Diagnostic Tests (Imaging Test) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hepatitis Diagnostic Tests (Liver Biopsy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hepatitis Diagnostic Tests (Liver Biopsy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: North America: Hepatitis Diagnostic Tests Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: North America: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Asia Pacific: Hepatitis Diagnostic Tests Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Asia Pacific: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Europe: Hepatitis Diagnostic Tests Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Europe: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Middle East and Africa: Hepatitis Diagnostic Tests Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Middle East and Africa: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Latin America: Hepatitis Diagnostic Tests Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Latin America: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Hepatitis Diagnostic Tests Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Hepatitis Diagnostic Tests Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
  • Table 3: Global: Hepatitis Diagnostic Tests Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 4: Global: Hepatitis Diagnostic Tests Market: Competitive Structure
  • Table 5: Global: Hepatitis Diagnostic Tests Market: Key Players